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Clinical PerspectiveWhat Is New?Imaging and/or genetic screening is not the current standard of care in relatives of patients affected by nonsyndromic thoracic aortic diseases (NS‐TADs).Genetic and/or imaging screening of relatives of patients affected by NS‐TAD can detect more than 30% of patients newly affected by thoracic aortic diseases.What Are the Clinical Implications?Routine imaging and genetic testing of relatives of patients affected by nonsyndromic aortopathies should be encouraged.The evidence suggests that screening of first‐ and second‐degree relatives of patients affected by familial NS‐TAD and first‐degree relatives of those affected by sporadic NS‐TADs will result in significant numbers of patients with otherwise undiagnosed disease.Personalized screening programs determined by the subtype of NS‐TAD and its related genetic mutation have the potential to benefit these patients.

Introduction {#jah33353-sec-0008}
============

Diseases of the thoracic aorta are increasing in prevalence, accounting for 1% to 2% of all deaths in Western countries.[1](#jah33353-bib-0001){ref-type="ref"}, [2](#jah33353-bib-0002){ref-type="ref"}, [3](#jah33353-bib-0003){ref-type="ref"}, [4](#jah33353-bib-0004){ref-type="ref"}, [5](#jah33353-bib-0005){ref-type="ref"} In the United States, diseases of the aorta account for more than 40 000 deaths per year.[1](#jah33353-bib-0001){ref-type="ref"}, [4](#jah33353-bib-0004){ref-type="ref"} Thoracic aortic diseases (TADs) are often silent entities with a mortality of almost 80% when presenting as life‐threatening emergencies.[3](#jah33353-bib-0003){ref-type="ref"}, [6](#jah33353-bib-0006){ref-type="ref"} Therefore, early diagnosis and treatment are likely to improve long‐term survival. TADs may be syndromic, associated with disorders involving other organs such as Marfan syndrome, or more commonly nonsyndromic, with manifestations restricted to the thoracic aorta.[4](#jah33353-bib-0004){ref-type="ref"}, [5](#jah33353-bib-0005){ref-type="ref"} Nonsyndromic TADs (NS‐TADs) may be familial, characterized by the presence of a family history and an autosomal dominant inheritance, or sporadic.[4](#jah33353-bib-0004){ref-type="ref"}, [5](#jah33353-bib-0005){ref-type="ref"}, [6](#jah33353-bib-0006){ref-type="ref"}, [7](#jah33353-bib-0007){ref-type="ref"} Unlike syndromic TADs, NS‐TADs are not evident from external physical features and abnormalities of other organ systems and are characterized by silent aneurysm formation and dissection.[4](#jah33353-bib-0004){ref-type="ref"}, [5](#jah33353-bib-0005){ref-type="ref"} Screening of first‐degree relatives (FDRs) of patients affected by NS‐TAD is therefore recommended for early detection and treatment of asymptomatic disease.[4](#jah33353-bib-0004){ref-type="ref"}, [5](#jah33353-bib-0005){ref-type="ref"} However, existing guidelines are based predominantly on the consensus of expert opinion, rather than high‐quality evidence, and the testing modality, frequency, and extent (FDRs versus second‐degree relatives \[SDRs\]) of screening are not defined.[4](#jah33353-bib-0004){ref-type="ref"}, [5](#jah33353-bib-0005){ref-type="ref"} As a consequence, there is widespread variation in the screening of family members of patients with NS‐TADs. To address this area of uncertainty, we performed a systematic review of the evidence for screening in the relatives of patients affected with NS‐TADs with reference to the prevalence of aortic disease, the predictive accuracy of genetic and imaging screening tests, and the effectiveness of screening programs in this high‐risk population.

Methods {#jah33353-sec-0009}
=======

The data, analytic methods, and study materials are available to other researchers for purposes of reproducing the results or replicating the procedure (Supplemental Material).

Protocol, Registration, and Search Strategy {#jah33353-sec-0010}
-------------------------------------------

The search strategy, objectives, study selection and eligibility, data collection, and assessment of study quality are published online and registered in the PROSPERO International Prospective Register of Systematic Reviews (PROSPERO registry---CRD42017064598).[8](#jah33353-bib-0008){ref-type="ref"} The protocol of the present systematic review is fully reported in Data [S1](#jah33353-sup-0001){ref-type="supplementary-material"}. The review adhered to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta‐Analyses) guidelines (Table [S1](#jah33353-sup-0001){ref-type="supplementary-material"}).[9](#jah33353-bib-0009){ref-type="ref"}

We searched electronic databases (PubMed/MEDLINE, Embase, and Cochrane Library) without date or language restriction from inception to the end of December 2017. A systematic search in the Online Mendelian Inheritance in Man (OMIM) database[10](#jah33353-bib-0010){ref-type="ref"} on December 31, 2017, was also accomplished. To supplement the electronic search, the "first‐generation" reference lists of pertinent articles were reviewed. Search criteria, adopted keywords, and MeSH terms used in relevant combinations are reported in Data [S1](#jah33353-sup-0001){ref-type="supplementary-material"}.

Participants {#jah33353-sec-0011}
------------

We included studies considering imaging and/or genetic screening tests in probands affected by diseases of the thoracic aorta (aneurysms and/or acute aortic syndrome), and their FDRs, SDRs, and third‐degree relatives (TDRs), with no restriction on ethnicity or age.

Target Condition {#jah33353-sec-0012}
----------------

The target condition was disease of the thoracic aorta (aneurysm and/or acute aortic syndrome) defined by the international guidelines on diagnosis and management of patients with TAD.[4](#jah33353-bib-0004){ref-type="ref"}, [5](#jah33353-bib-0005){ref-type="ref"} Only NS‐TAD forms were considered in the present review; syndromic TADs or other *forme fruste* of syndromic TAD related to the transforming growth factor β pathway were excluded. Familial NS‐TAD forms were defined as those occurring in families with ≥2 members with a known TAD, but without a clinical diagnosis or history of a syndromic TAD or any other connective tissue disease.[7](#jah33353-bib-0007){ref-type="ref"} Sporadic TADs were defined as those occurring in patients apparently without a family history of TAD or evidence of syndromic TAD.[4](#jah33353-bib-0004){ref-type="ref"}, [5](#jah33353-bib-0005){ref-type="ref"}, [7](#jah33353-bib-0007){ref-type="ref"}

Index Tests {#jah33353-sec-0013}
-----------

For the purposes of the review, we included studies that phenotyped participants using the following imaging tests: transthoracic echocardiogram (TTE)/transoesophageal echocardiogram, computed tomography (CT), or magnetic resonance imaging (MRI) of the thoracic aorta, and genetic screening, individually or in combination with the acknowledgement that sensitivities and specificities of CT (100% and 100%, respectively) and MRI (95--100%) are higher when compared with those of transoesophageal echocardiogram and TTE (74--100% and 71--91%, respectively).[11](#jah33353-bib-0011){ref-type="ref"}, [12](#jah33353-bib-0012){ref-type="ref"}, [13](#jah33353-bib-0013){ref-type="ref"}, [14](#jah33353-bib-0014){ref-type="ref"}, [15](#jah33353-bib-0015){ref-type="ref"} In some studies, surgery for TAD, postmortem examination, or sudden death were used to assess the aortic phenotype. Molecular genetic testing approaches included a combination of gene‐targeted testing (multigene panel or single gene testing) and whole exome of genome sequencing.[16](#jah33353-bib-0016){ref-type="ref"}, [17](#jah33353-bib-0017){ref-type="ref"}, [18](#jah33353-bib-0018){ref-type="ref"}

Study Selection, Data Collection, and Extraction {#jah33353-sec-0014}
------------------------------------------------

Two investigators (G.M. and R.D.) independently reviewed titles, abstracts, and full‐text articles against the specified inclusion criteria for studies regarding screening of relatives of patients with NS‐TADs. Discrepancies were resolved through consensus and consultation with a third investigator (G.J.M.). One reviewer extracted key data from the included studies using a standard dedicated pro forma; a second reviewer checked the collected data for completeness and accuracy. The Tables report full details on study design and quality, setting and population, details, and results of screening. Key study characteristics include details of the patient population (NS‐TAD form, ethnicity, family identification), participants undergoing screening (relatives eligible for screening; family pedigree; total number of screened relatives; numbers of FDRs, SDRs, and TDRs), TAD characteristics (new diagnosis of aortic disease, number/rate of newly diagnosed thoracic aortic aneurysms and/or dissection, rate of unexplained sudden death, age and aortic diameters at dissection, sex preponderance, and aortic disease penetrance), additional concomitant phenotype/clinical features (types and rates), and type of adopted screening modality (imaging and genetic test used, validation processes). The definitions of the extracted variables are fully reported in Data [S1](#jah33353-sup-0001){ref-type="supplementary-material"}.

Quality Assessment, Data Synthesis, and Analysis {#jah33353-sec-0015}
------------------------------------------------

Two investigators (G.M., R.D.) independently appraised all articles that met inclusion criteria. Study quality was assessed using the Newcastle‐Ottawa Scale and the US Preventive Services Task Force.[19](#jah33353-bib-0019){ref-type="ref"}, [20](#jah33353-bib-0020){ref-type="ref"} The Cochrane Risk of Bias tool was also used to evaluate the methodological quality of all included studies.[21](#jah33353-bib-0021){ref-type="ref"}

Because of the observational nature of the studies and their clinical heterogeneity, the analyses were largely descriptive, and a narrative and tabular synthesis of all included studies is provided. Inclusion and exclusion criteria for qualitative/quantitative analyses are summarized according to the PICOS (population, intervention, comparator, outcomes, and study design) approach (Table [S2](#jah33353-sup-0001){ref-type="supplementary-material"}). Subgroup analysis considering type of NS‐TAD form, aortic disease (aneurysm and/or dissection), genetic mutation, and screening modality was also conducted. Categorical variables are reported as number and percentage, and continuous variables are reported as mean and SD or median and range, according to distribution. Analyses were performed with SPSS version 24.0 (IBM).

Results {#jah33353-sec-0016}
=======

Description of Studies and Quality Assessment {#jah33353-sec-0017}
---------------------------------------------

Of the 12 897 records identified, 53 studies were included in the systematic review, comprising a total of 2696 screened relatives. The studies were published between 1985 and 2017 (Figure [S1](#jah33353-sup-0001){ref-type="supplementary-material"}).[22](#jah33353-bib-0022){ref-type="ref"}, [23](#jah33353-bib-0023){ref-type="ref"}, [24](#jah33353-bib-0024){ref-type="ref"}, [25](#jah33353-bib-0025){ref-type="ref"}, [26](#jah33353-bib-0026){ref-type="ref"}, [27](#jah33353-bib-0027){ref-type="ref"}, [28](#jah33353-bib-0028){ref-type="ref"}, [29](#jah33353-bib-0029){ref-type="ref"}, [30](#jah33353-bib-0030){ref-type="ref"}, [31](#jah33353-bib-0031){ref-type="ref"}, [32](#jah33353-bib-0032){ref-type="ref"}, [33](#jah33353-bib-0033){ref-type="ref"}, [34](#jah33353-bib-0034){ref-type="ref"}, [35](#jah33353-bib-0035){ref-type="ref"}, [36](#jah33353-bib-0036){ref-type="ref"}, [37](#jah33353-bib-0037){ref-type="ref"}, [38](#jah33353-bib-0038){ref-type="ref"}, [39](#jah33353-bib-0039){ref-type="ref"}, [40](#jah33353-bib-0040){ref-type="ref"}, [41](#jah33353-bib-0041){ref-type="ref"}, [42](#jah33353-bib-0042){ref-type="ref"}, [43](#jah33353-bib-0043){ref-type="ref"}, [44](#jah33353-bib-0044){ref-type="ref"}, [45](#jah33353-bib-0045){ref-type="ref"}, [46](#jah33353-bib-0046){ref-type="ref"}, [47](#jah33353-bib-0047){ref-type="ref"}, [48](#jah33353-bib-0048){ref-type="ref"}, [49](#jah33353-bib-0049){ref-type="ref"}, [50](#jah33353-bib-0050){ref-type="ref"}, [51](#jah33353-bib-0051){ref-type="ref"}, [52](#jah33353-bib-0052){ref-type="ref"}, [53](#jah33353-bib-0053){ref-type="ref"}, [54](#jah33353-bib-0054){ref-type="ref"}, [55](#jah33353-bib-0055){ref-type="ref"}, [56](#jah33353-bib-0056){ref-type="ref"}, [57](#jah33353-bib-0057){ref-type="ref"}, [58](#jah33353-bib-0058){ref-type="ref"}, [59](#jah33353-bib-0059){ref-type="ref"}, [60](#jah33353-bib-0060){ref-type="ref"}, [61](#jah33353-bib-0061){ref-type="ref"}, [62](#jah33353-bib-0062){ref-type="ref"}, [63](#jah33353-bib-0063){ref-type="ref"}, [64](#jah33353-bib-0064){ref-type="ref"}, [65](#jah33353-bib-0065){ref-type="ref"}, [66](#jah33353-bib-0066){ref-type="ref"}, [67](#jah33353-bib-0067){ref-type="ref"}, [68](#jah33353-bib-0068){ref-type="ref"}, [69](#jah33353-bib-0069){ref-type="ref"}, [70](#jah33353-bib-0070){ref-type="ref"}, [71](#jah33353-bib-0071){ref-type="ref"}, [72](#jah33353-bib-0072){ref-type="ref"}, [73](#jah33353-bib-0073){ref-type="ref"}, [74](#jah33353-bib-0074){ref-type="ref"} Regions of origin included North America (28 studies), Europe (17 studies), Asia (5 studies), and Australia (3 studies) (Table [1](#jah33353-tbl-0001){ref-type="table"}). No randomized trials were identified, and only 1 large cross‐sectional study was conducted including 581 at‐risk relatives.[58](#jah33353-bib-0058){ref-type="ref"} Study characteristics and collected outcomes are summarized in Tables [S3](#jah33353-sup-0001){ref-type="supplementary-material"} through [S8](#jah33353-sup-0001){ref-type="supplementary-material"} and study quality assessment in Table [S9](#jah33353-sup-0001){ref-type="supplementary-material"}.

###### 

Details of Studies Included in the Systematic Review

  Study (Author/Y)                                                                                        Country                                                NS‐TAD Form     Pedigree (Patients)   Relatives Affected   Penetrance, %   Inheritance (Modality)   Type of Screening                           Related Gene                                
  ------------------------------------------------------------------------------------------------------- ------------------------------------------------------ --------------- --------------------- -------------------- --------------- ------------------------ ------------------------------------------- -------------- ----- ----- ----- ---------- ---------------------------------------------------------
  Barbier et al 2014[22](#jah33353-bib-0022){ref-type="ref"}                                              France                                                 FTAAD           40                    14                   14              0                        2                                           7              18    60    AD    GEN+IMAG   MFAP5
  Bee et al 2012[23](#jah33353-bib-0023){ref-type="ref"}                                                  United States                                          FTAA            54                    37                   3               0                        9                                           12             22    100   ···   GEN        ACTA2, MYH11, TGFBR2
  Chamney et al 2015[24](#jah33353-bib-0024){ref-type="ref"}                                              United Kingdom                                         FTAAD           14                    8                    3               0                        1                                           5              36    100   AD    GEN+IMAG   ACTA2
  Disabella et al 2011[25](#jah33353-bib-0025){ref-type="ref"}                                            Italy                                                  FTAAD           37                    23                   5               4                        5                                           10             27    78    AD    GEN+IMAG   ACTA2
  Disertori et al 1991[26](#jah33353-bib-0026){ref-type="ref"}                                            Italy                                                  FTAAD           30                    13                   15              0                        2                                           2              7     na    ···   IMAG       ···
  Dong et al 2014[27](#jah33353-bib-0027){ref-type="ref"}                                                 China                                                  FTAAD           64                    5                    9               30                       1                                           8              13    64    ···   GEN+IMAG   TGFBR1
  Francke et al 1995[28](#jah33353-bib-0028){ref-type="ref"}                                              United States                                          FTAAD           26                    15                   9               0                        1                                           9              35    67    AD    GEN+IMAG   FBN1
  Gago‐Diaz et al 2014[29](#jah33353-bib-0029){ref-type="ref"}                                            Spain                                                  FTAAD           31                    3                    10              13                       1                                           6              19    60    AD    GEN        TGFB2
  Gago‐Diaz et al 2016[30](#jah33353-bib-0030){ref-type="ref"}                                            Spain                                                  FTAAD           30                    12                   14              3                        1                                           10             33    88    AD    GEN        PRKG1
  Guo et al 2001[31](#jah33353-bib-0031){ref-type="ref"}                                                  United States[a](#jah33353-note-0003){ref-type="fn"}   FTAAD           219                   n/c                  n/c             n/c                      n/a                                         n/c            n/c   n/a   AD    GEN        Locus 5q13‐14[b](#jah33353-note-0004){ref-type="fn"}
  Guo et al 2007[32](#jah33353-bib-0032){ref-type="ref"}                                                  United States[a](#jah33353-note-0003){ref-type="fn"}   FTAAD           212                   n/c                  n/c             n/c                      n/a                                         n/c            n/c   48    AD    GEN        ACTA2
  Guo et al 2009[33](#jah33353-bib-0033){ref-type="ref"}                                                  United States[a](#jah33353-note-0003){ref-type="fn"}   FTAAD           269                   n/c                  n/c             n/c                      n/a                                         n/c            n/c   49    AD    GEN        ACTA2
  Guo et al 2011[34](#jah33353-bib-0034){ref-type="ref"}                                                  United States[a](#jah33353-note-0003){ref-type="fn"}   FTAAD/pAA       28                    7                    9               6                        1                                           8              29    75    AD    GEN        Locus 12q13‐14[b](#jah33353-note-0004){ref-type="fn"}
  Guo et al 2013[35](#jah33353-bib-0035){ref-type="ref"}                                                  United States[a](#jah33353-note-0003){ref-type="fn"}   FTAAD           89                    40                   18              12                       6                                           31             35    100   AD    GEN        PRKG1
  Guo et al 2015[36](#jah33353-bib-0036){ref-type="ref"}                                                  United States[a](#jah33353-note-0003){ref-type="fn"}   BAV/TAA         48                    10                   14              15                       1                                           7              15    44    AD    GEN        MATA2
  Guo et al 2016[37](#jah33353-bib-0037){ref-type="ref"}                                                  United States[a](#jah33353-note-0003){ref-type="fn"}   FTAAD           65                    21                   22              13                       6                                           15             23    86    AD    GEN        LOX
  Hannuksela et al 2015[38](#jah33353-bib-0038){ref-type="ref"}                                           Sweden                                                 FTAAD           270                   60                   89              55                       7                                           37             14    n/a   ···   GEN+IMAG   ···
  Hannuksela et al 2016[39](#jah33353-bib-0039){ref-type="ref"}                                           Sweden                                                 FTAAD           46                    n/c                  n/c             n/c                      1                                           n/c            n/c   45    ···   GEN+IMAG   MYLK
  Harakalova et al 2013[40](#jah33353-bib-0040){ref-type="ref"}                                           Holland                                                TAAD/PDA        75                    6                    15              34                       2                                           13             17    45    AD    GEN        MYH11
  Hasham et al 2003[41](#jah33353-bib-0041){ref-type="ref"}                                               United States[a](#jah33353-note-0003){ref-type="fn"}   FTAAD           69                    4                    5               39                       1                                           16             23    75    AD    GEN+IMAG   TGFBR2
  Kakko et al 2003[42](#jah33353-bib-0042){ref-type="ref"}                                                Finland                                                FTAAD           213                   n/c                  n/c             n/c                      n/a                                         n/c            n/c   n/a   ···   GEN+IMAG   Locus 5q13‐14[b](#jah33353-note-0004){ref-type="fn"}
  Kent et al 2013[43](#jah33353-bib-0043){ref-type="ref"}                                                 United States                                          BAV/TAA         129                   73                   21              19                       14                                          34             26    n/a   AD    GEN+IMAG   NOTCH1
  Keramati et al 2010[44](#jah33353-bib-0044){ref-type="ref"}                                             United States                                          FTAAD           23                    10                   8               0                        1                                           12             52    90    AD    GEN+IMAG   Locus 15q21 (FBN1?)
  Khau Van Kien et al 2004[45](#jah33353-bib-0045){ref-type="ref"}                                        France                                                 FTAAD/PDA       68                    13                   21              24                       1                                           7              10    n/a   AD    GEN+IMAG   ···
  Khau Van Kien et al 2005[46](#jah33353-bib-0046){ref-type="ref"}                                        France                                                 FTAAD/PDA       87                    13                   26              38                       1                                           7              8     50    AD    GEN+IMAG   MYH11
  Kuang et al 2016[47](#jah33353-bib-0047){ref-type="ref"}                                                United States[a](#jah33353-note-0003){ref-type="fn"}   FTAAD           40                    n/c                  n/c             n/c                      n/a                                         n/c            n/c   75    AD    GEN        FOXE3
  Loscalzo et al 2007[48](#jah33353-bib-0048){ref-type="ref"}                                             United States                                          BAV/TAA         194                   72                   37              65                       13                                          44             23    88    AD    GEN+IMAG   ···
  Marwick et al 1987[49](#jah33353-bib-0049){ref-type="ref"}                                              Australia                                              FTADiss         17                    7                    5               0                        1                                           1              6     n/a   ···   IMAG       ···
  McManus et al 1987[50](#jah33353-bib-0050){ref-type="ref"}                                              United States                                          FTADiss         19                    7                    9               0                        1                                           5              26    n/a   ···   IMAG       ···
  Milewicz et al 1998[51](#jah33353-bib-0051){ref-type="ref"}                                             United States[a](#jah33353-note-0003){ref-type="fn"}   FTAAD           123                   44                   44              7                        6                                           24             20    n/a   AD    GEN+IMAG   ···[c](#jah33353-note-0005){ref-type="fn"}
  Morisaki et al 2009[52](#jah33353-bib-0052){ref-type="ref"}                                             Japan                                                  FTAAD           47                    10                   6               27                       3                                           11             23    100   ···   GEN        ACTA2
  Pannu et al 2005[53](#jah33353-bib-0053){ref-type="ref"}                                                United States[a](#jah33353-note-0003){ref-type="fn"}   FTAAD           235                   18                   35              121                      4                                           54             23    79    AD    GEN+IMAG   TGFBR2
  Pannu et al 2007[54](#jah33353-bib-0054){ref-type="ref"}                                                United States[a](#jah33353-note-0003){ref-type="fn"}   FTAAD           27                    16                   4               0                        2                                           4              15    45    ···   GEN+IMAG   MYH11
  Regalado et al 2011[55](#jah33353-bib-0055){ref-type="ref"}                                             United States[a](#jah33353-note-0003){ref-type="fn"}   FTAAD/ICA       231                   83                   64              50                       13[d](#jah33353-note-0006){ref-type="fn"}   43             19    n/a   AD    GEN        ACTA2, TGFBR1, TGFBR2
  Regalado et al 2011[56](#jah33353-bib-0056){ref-type="ref"}                                             United States[a](#jah33353-note-0003){ref-type="fn"}   FTAAD/ICA/pAA   106                   n/c                  n/c             n/c                      n/a                                         n/c            n/c   65    AD    GEN        SMAD3
  Regalado et al 2011[57](#jah33353-bib-0057){ref-type="ref"}                                             United States[a](#jah33353-note-0003){ref-type="fn"}   FTAAD           29                    18                   6               0                        5                                           10             34    n/a   ···   GEN        FBN1
  Renard et al 2013[58](#jah33353-bib-0058){ref-type="ref"}                                               Belgium                                                FTAAD           97                    34                   30              7                        8                                           21             22    n/a   AD    GEN        ACTA2, MYH11
  Robertson et al 2016[59](#jah33353-bib-0059){ref-type="ref"}                                            Australia                                              FTAAD           n/c                   n/c                  n/c             n/c                      270                                         341            56    n/a   ···   IMAG       ···
  Sherrah et al 2016[60](#jah33353-bib-0060){ref-type="ref"}                                              Australia                                              FTAAD           n/c                   n/c                  n/c             n/c                      n/a                                         n/c            n/c   n/a   ···   IMAG       ···
  Takeda et al 2015[61](#jah33353-bib-0061){ref-type="ref"}                                               Japan                                                  FTAAD           17                    5                    6               2                        1                                           4              24    75    ···   GEN        MYH11
  Teixidó‐Turà et al 2014[62](#jah33353-bib-0062){ref-type="ref"}                                         Spain                                                  FTAAD           36                    8                    5               15                       1                                           2              6     10    ···   GEN        ACTA2
  Tortora et al 2017[63](#jah33353-bib-0063){ref-type="ref"}                                              Italy                                                  BAV/TAA         97                    77                   0               0                        20                                          5              7     n/a   ···   GEN+IMAG   ···[e](#jah33353-note-0007){ref-type="fn"}
  Tran‐Fadulo et al 2006[64](#jah33353-bib-0064){ref-type="ref"}                                          United States[a](#jah33353-note-0003){ref-type="fn"}   FTAAD           153                   14                   45              63                       3                                           18             12    n/a   ···   GEN        ···
  Tran‐Fadulo et al 2009[65](#jah33353-bib-0065){ref-type="ref"}                                          United States[a](#jah33353-note-0003){ref-type="fn"}   FTAAD           78                    31                   23              7                        4[f](#jah33353-note-0008){ref-type="fn"}    26             33    70    AD    GEN        TGFBR1
  Vaughan et al 2001[66](#jah33353-bib-0066){ref-type="ref"}                                              United States[a](#jah33353-note-0003){ref-type="fn"}   FTAA            67                    27                   20              2                        3                                           27             40    n/a   AD    GEN+IMAG   Locus 11q23.3‐24[b](#jah33353-note-0004){ref-type="fn"}
  Wang et al 2010[67](#jah33353-bib-0067){ref-type="ref"}                                                 United States[a](#jah33353-note-0003){ref-type="fn"}   FTADiss         48                    n/c                  n/c             n/c                      n/a                                         n/c            n/c   50    AD    GEN        MYLK
  Wang et al 2013[68](#jah33353-bib-0068){ref-type="ref"}                                                 China                                                  FTAAD           10                    7                    0               0                        1                                           1              10    n/a   ···   GEN        ···
  Ware et al 2014[69](#jah33353-bib-0069){ref-type="ref"}                                                 United States                                          FTAAD           7                     4                    0               0                        2                                           0              0     100   ···   GEN        ACTA2
  Warnes et al 1985[70](#jah33353-bib-0070){ref-type="ref"}                                               United States                                          FTAAD           6                     4                    0               0                        2                                           0              0     n/a   ···   IMAG       ···
  Weigang et al 2007[71](#jah33353-bib-0071){ref-type="ref"}                                              Germany                                                FTAAD           26                    n/c                  n/c             n/c                      n/a                                         n/c            n/c   n/a   AD    GEN+IMAG   ···
  Yoo et al 2010[72](#jah33353-bib-0072){ref-type="ref"}                                                  Korea                                                  FTAAD           20                    7                    7               0                        1                                           4              20    67    AD    GEN        ACTA2
  Zhu et al 2006[73](#jah33353-bib-0073){ref-type="ref"}                                                  France                                                 FTAAD/PDA       49                    n/c                  n/c             n/c                      n/a                                         n/c            n/c   44    AD    GEN+IMAG   MYH11
  Ziganshin et al 2015[74](#jah33353-bib-0074){ref-type="ref"}, [g](#jah33353-note-0009){ref-type="fn"}   United States                                          FTAAD           27                    7                    11              2                        1                                           3              11    70    AD    GEN        MYLK
  Ziganshin et al 2015[74](#jah33353-bib-0074){ref-type="ref"}, [g](#jah33353-note-0009){ref-type="fn"}   United States                                          FTAAD           17                    6                    8               0                        1                                           6              35    70    ···   GEN        TGFBR1

AD indicates autosomal dominant; BAV, bicuspid aortic valve; FDRs, first‐degree relatives; FTAA, familial thoracic aortic aneurysm; FTADiss, familial aortic dissection; FTAAD, familial thoracic aortic aneurysm and dissection; GEN, genetic; ICA, intracranial aneurysm; IMAG, imaging; n/a, not available; NS‐TAD, nonsyndromic thoracic aortic disease; n/c, not computable; pAA, peripheral artery aneurysm; PDA, patent ductus arteriosus; SDRs, second‐degree relatives; TAA, thoracic aortic aneurysm; TAAD, thoracic aortic aneurysm and/or dissection; TDRs, third‐degree relatives.

Study performed at University of Texas.

Mapped loci without identified gene.

No linkage to FBN1 or TAAD2.

Four probands not affected by aortic diseases (aortic aneurysm and/or dissections).

No linkage with ACTA2.

One proband not affected by aortic diseases (aortic aneurysm and/or dissection).

Data of 2 different screened families obtained from the same study.

Target Condition {#jah33353-sec-0018}
----------------

Four main groups of familial NS‐TADs were identified: (1) those characterized by the presence of both aneurysms and dissections in the family pedigree (familial thoracic aortic aneurysm and dissection; 44 studies); (2) those characterized by aneurysmal disease only (familial thoracic aortic aneurysm; 2 studies); (3) those characterized by aortic dissection only (familial thoracic aortic dissection; 3 studies); and (4) thoracic aortic aneurysm forms associated with the presence of bicuspid aortic valve (4 studies). Among the familial thoracic aortic aneurysm and dissection forms, 3 additional subgroups were discovered based on the concomitant presence of patent ductus arteriosus (n=4), intracranial aneurysms (n=2), or peripheral arterial aneurysms (n=2) (Table [1](#jah33353-tbl-0001){ref-type="table"}).

Index Tests {#jah33353-sec-0019}
-----------

Screening for TAD was performed using 2‐dimensional TTE in 27 (51%) studies, of which 15 (28%) employed 2‐dimensional TTE alone and the remaining 8 (15%) used 2‐dimensional TTE in association with CT and/or MRI. In 5 (9%) studies only, imaging screening included the simultaneous employment of 2‐dimensional TTE, CT, and MRI. In a further 26 (49%) studies, aortic phenotype (presence of an aortic aneurysm and/or dissection) was defined by reported clinical events including acute aortic syndrome, diagnosis made during routine diagnostic clinical care, or postmortem examination. The aortic diameter cutoff used for defining a critical dilation of the aorta varied among studies as the aortic site where the measurements were made (Table [S7](#jah33353-sup-0001){ref-type="supplementary-material"}).

No study reported the sensitivity, specificity, or other measures of diagnostic accuracy for the index tests. One study reported 10‐year longitudinal follow‐up for relatives of patients with NS‐TAD.[59](#jah33353-bib-0059){ref-type="ref"} In this study, relatives with evidence of aortic dilatation were offered annual follow‐up imaging with prescription of β‐blockers or angiotensin receptor blockers at maximal tolerated doses. Relatives with no evidence of aortic dilatation (unaffected) were subjected to clinical review every 3 years. In the affected relatives (n=114) with serial aortic measurements over 4.5±4.4 years, a mean rate of increase in the aortic diameter of 0.56±0.76 mm per year was observed. No difference in the rate of aortic dilatation was observed between males and females or in patients receiving β‐blockers or angiotensin receptor blockers. No correlation with the age at diagnosis, the initial aortic diameter, and the systolic or diastolic blood pressure was documented. During 10‐year follow‐up, 9% of newly diagnosed relatives were affected by an aortic dissection, and 18% underwent elective aortic surgery. Six relatives (of 368) originally diagnosed as unaffected (initial aortic diameter with a *Z* score \<2) experienced a subsequent aortic dissection.[59](#jah33353-bib-0059){ref-type="ref"}

Results of Imaging Tests {#jah33353-sec-0020}
------------------------

A total of 1039 families underwent screening for NS‐TAD, with a median number of patients in each family pedigree of 48 (study range: 6--270) (Table [S3](#jah33353-sup-0001){ref-type="supplementary-material"}). The proportion of potential eligible patients per family was 73% (study range: 50--100%), while the rate of relatives effectively screened was 54% (study range: 5--100%) (Table [2](#jah33353-tbl-0002){ref-type="table"} and Table [S4](#jah33353-sup-0001){ref-type="supplementary-material"}). FDRs, SDRs, and TDRs were variably screened throughout the studies. Twelve percent of FDRs, 24% of SDRs, and 18% of TDRs were not available for screening (Figure [1](#jah33353-fig-0001){ref-type="fig"}).

###### 

Details of Newly Diagnosed Diseases of the Thoracic Aorta in the Screened Relatives

  Study (Author/Y)                                                                                        No. of Relatives Screened                    Patients Affected[a](#jah33353-note-0011){ref-type="fn"} (Aortic Aneurysm+Aortic Dissection)   Sudden Death (Unexplained)   Aortic Aneurysm[a](#jah33353-note-0011){ref-type="fn"}   Aortic Dissection[a](#jah33353-note-0011){ref-type="fn"}                                                                                                                                                              
  ------------------------------------------------------------------------------------------------------- -------------------------------------------- ---------------------------------------------------------------------------------------------- ---------------------------- -------------------------------------------------------- ---------------------------------------------------------- ----- ----- ------------------------------------------ ----- ------------------------------------------- ----- ------------------------------------------- --------
  Barbier et al 2014[22](#jah33353-bib-0022){ref-type="ref"}                                              13                                           9                                                                                              23                           3                                                        33                                                         n/a   ···   8                                          89    1                                           11    58                                          n/a
  Bee et al 2012[23](#jah33353-bib-0023){ref-type="ref"}                                                  32                                           21                                                                                             39                           16                                                       76                                                         n/a   ···   21                                         100   0                                           0     ···                                         ···
  Chamney et al 2015[24](#jah33353-bib-0024){ref-type="ref"}                                              6                                            6                                                                                              43                           4                                                        67                                                         0     0     3                                          50    3                                           50    49±10.4                                     37--55
  Disabella et al 2011[25](#jah33353-bib-0025){ref-type="ref"}                                            29                                           15                                                                                             41                           8                                                        53                                                         1     3     6                                          40    9                                           60    49.3±16.3                                   29--73
  Disertori et al 1991[26](#jah33353-bib-0026){ref-type="ref"}                                            14                                           4                                                                                              13                           4                                                        100                                                        n/a   ···   2                                          50    2                                           50    46±2.8                                      44--48
  Dong et al 2014[27](#jah33353-bib-0027){ref-type="ref"}                                                 39                                           9                                                                                              14                           7                                                        78                                                         1     2     6                                          67    3                                           33    39±6.9                                      35--47
  Francke et al 1995[28](#jah33353-bib-0028){ref-type="ref"}                                              23                                           10                                                                                             38                           6                                                        60                                                         n/a   ···   8                                          80    2                                           20    55±14.1                                     45--65
  Gago‐Diaz et al 2014[29](#jah33353-bib-0029){ref-type="ref"}                                            12                                           7                                                                                              23                           5                                                        71                                                         n/a   ···   5                                          71    2                                           29    37.5±4.9                                    34--41
  Gago‐Diaz et al 2016[30](#jah33353-bib-0030){ref-type="ref"}                                            14                                           11                                                                                             37                           6                                                        55                                                         1     3     5                                          45    6                                           55    34.2±12.9                                   15--48
  Guo et al 2001[31](#jah33353-bib-0031){ref-type="ref"}                                                  121                                          73                                                                                             33                           47                                                       64                                                         n/a   ···   n/a                                        ···   n/a                                         ···   ···                                         ···
  Guo et al 2007[32](#jah33353-bib-0032){ref-type="ref"}                                                  130                                          53                                                                                             25                           33                                                       62                                                         n/a   ···   8                                          15    45                                          85    37.3±13.9                                   13--67
  Guo et al 2009[33](#jah33353-bib-0033){ref-type="ref"}                                                  163                                          66                                                                                             25                           39                                                       59                                                         n/a   ···   n/a                                        ···   n/a                                         ···   ···                                         ···
  Guo et al 2011[34](#jah33353-bib-0034){ref-type="ref"}                                                  18                                           9                                                                                              32                           9                                                        100                                                        n/a   ···   8                                          89    1                                           11    32                                          n/a
  Guo et al 2013[35](#jah33353-bib-0035){ref-type="ref"}                                                  39                                           37                                                                                             42                           16                                                       43                                                         n/a   ···   15                                         41    22                                          59    31.1±10.3                                   17--51
  Guo et al 2015[36](#jah33353-bib-0036){ref-type="ref"}                                                  34                                           8                                                                                              17                           5                                                        63                                                         1     2     8                                          100   0                                           0     ···                                         ···
  Guo et al 2016[37](#jah33353-bib-0037){ref-type="ref"}                                                  21                                           21                                                                                             32                           17                                                       81                                                         2     3     17                                         81    4                                           19    44.8±15.1                                   25--60
  Hannuksela et al 2015[38](#jah33353-bib-0038){ref-type="ref"}                                           106                                          44                                                                                             17                           32                                                       73                                                         0     0     27                                         61    17                                          39    48[b](#jah33353-note-0012){ref-type="fn"}   15--75
  Hannuksela et al 2016[39](#jah33353-bib-0039){ref-type="ref"}                                           19                                           6                                                                                              13                           4                                                        67                                                         0     0     0                                          0     6                                           100   53.2±21.1                                   23--75
  Harakalova et al 2013[40](#jah33353-bib-0040){ref-type="ref"}                                           40                                           15                                                                                             20                           10                                                       67                                                         3     4     4                                          37    11                                          73    46.6±19.5                                   18--70
  Hasham et al 2003[41](#jah33353-bib-0041){ref-type="ref"}                                               52                                           17                                                                                             25                           14                                                       82                                                         n/a   ···   9                                          53    8                                           47    45.4±21.5                                   14--72
  Kakko et al 2003[42](#jah33353-bib-0042){ref-type="ref"}                                                115                                          39                                                                                             18                           25                                                       64                                                         n/a   ···   26                                         67    13                                          33    53.2±15.5                                   26--80
  Kent et al 2013[43](#jah33353-bib-0043){ref-type="ref"}                                                 93                                           48                                                                                             37                           37                                                       77                                                         n/a   ···   n/a                                        ···   n/a                                         ···   ···                                         ···
  Keramati et al 2010[44](#jah33353-bib-0044){ref-type="ref"}                                             15                                           13                                                                                             57                           6                                                        46                                                         n/a   ···   10                                         77    3                                           23    n/a                                         n/a
  Khau Van Kien et al 2004[45](#jah33353-bib-0045){ref-type="ref"}                                        49                                           8                                                                                              12                           6                                                        75                                                         3     4     4                                          50    4                                           50    n/a                                         n/a
  Khau Van Kien et al 2005[46](#jah33353-bib-0046){ref-type="ref"}                                        78                                           8                                                                                              9                            6                                                        75                                                         2     2     4                                          50    4                                           50    n/a                                         n/a
  Kuang et al 2016[47](#jah33353-bib-0047){ref-type="ref"}                                                16                                           11                                                                                             28                           11                                                       100                                                        n/a   ···   0                                          0     11                                          100   44.3±22.6                                   9--88
  Loscalzo et al 2007[48](#jah33353-bib-0048){ref-type="ref"}                                             138                                          57                                                                                             29                           42                                                       74                                                         n/a   ···   n/a                                        ···   n/a                                         ···   ···                                         ···
  Marwick et al 1987[49](#jah33353-bib-0049){ref-type="ref"}                                              4                                            2                                                                                              12                           1                                                        50                                                         0     0     0                                          0     2                                           100   26.5±3.5                                    24--29
  McManus et al 1987[50](#jah33353-bib-0050){ref-type="ref"}                                              8                                            6                                                                                              32                           5                                                        83                                                         n/a   ···   0                                          0     6                                           100   33.5±14.9                                   22--62
  Milewicz et al 1998[51](#jah33353-bib-0051){ref-type="ref"}                                             n/a                                          30                                                                                             24                           18                                                       60                                                         9     7     12                                         40    18                                          60    42.9±11.3                                   22--62
  Morisaki et al 2009[52](#jah33353-bib-0052){ref-type="ref"}                                             9                                            14                                                                                             30                           10                                                       71                                                         5     11    3                                          21    11                                          79    36.8±10.1                                   25--52
  Pannu et al 2005[53](#jah33353-bib-0053){ref-type="ref"}                                                72                                           58                                                                                             25                           39                                                       66                                                         n/a   ···   27                                         46    32                                          54    46.1±16.3                                   14--73
  Pannu et al 2007[54](#jah33353-bib-0054){ref-type="ref"}                                                23                                           6                                                                                              22                           4                                                        67                                                         n/a   ···   1                                          17    5                                           83    45±8.8                                      37--56
  Regalado et al 2011[55](#jah33353-bib-0055){ref-type="ref"}                                             12                                           52                                                                                             23                           35                                                       67                                                         7     3     9[c](#jah33353-note-0013){ref-type="fn"}   17    43[b](#jah33353-note-0012){ref-type="fn"}   83    50.8±13.7                                   25--76
  Regalado et al 2011[56](#jah33353-bib-0056){ref-type="ref"}                                             36                                           23                                                                                             22                           14                                                       61                                                         1     1     9                                          39    14                                          61    42[d](#jah33353-note-0014){ref-type="fn"}   25--54
  Regalado et al 2011[57](#jah33353-bib-0057){ref-type="ref"}                                             11                                           15                                                                                             52                           8                                                        53                                                         n/a   ···   7                                          47    8                                           53    32.3±9.9                                    18--50
  Renard et al 2013[58](#jah33353-bib-0058){ref-type="ref"}                                               29                                           29                                                                                             30                           16                                                       55                                                         3     3     14                                         48    15                                          52    48.0±21.2                                   33--63
  Robertson et al 2016[59](#jah33353-bib-0059){ref-type="ref"}                                            581                                          486                                                                                            38                           266                                                      72                                                         n/a   ···   370                                        76    116                                         24    50±13                                       n/a
  Sherrah et al 2016[60](#jah33353-bib-0060){ref-type="ref"}                                              119[e](#jah33353-note-0015){ref-type="fn"}   n/a                                                                                            n/a                          68                                                       76                                                         n/a   ···   n/a                                        ···   n/a                                         ···   n/a                                         ···
  Takeda et al 2015[61](#jah33353-bib-0061){ref-type="ref"}                                               9                                            5                                                                                              29                           4                                                        80                                                         0     0     1                                          20    4                                           80    47.8±16.6                                   32--70
  Teixidó‐Turà et al 2014[62](#jah33353-bib-0062){ref-type="ref"}                                         10                                           3                                                                                              8                            2                                                        67                                                         1     3     1                                          33    2                                           67    46.5±12                                     38--55
  Tortora et al 2017[63](#jah33353-bib-0063){ref-type="ref"}                                              77                                           25                                                                                             26                           61                                                       79                                                         n/a   ···   25                                         100   0                                           0     ···                                         ···
  Tran‐Fadulo et al 2006[64](#jah33353-bib-0064){ref-type="ref"}                                          9                                            21                                                                                             14                           7                                                        33                                                         0     0     4                                          19    17                                          81    32.0±12.3                                   16--55
  Tran‐Fadulo et al 2009[65](#jah33353-bib-0065){ref-type="ref"}                                          49                                           29                                                                                             37                           17                                                       59                                                         0     0     15                                         52    14                                          48    n/a                                         14--62
  Vaughan et al 2001[66](#jah33353-bib-0066){ref-type="ref"}                                              63                                           30                                                                                             45                           8                                                        27                                                         n/a   ···   n/a                                        ···   n/a                                         ···   ···                                         ···
  Wang et al 2010[67](#jah33353-bib-0067){ref-type="ref"}                                                 21                                           10                                                                                             21                           5                                                        50                                                         2     4     0                                          0     10                                          100   54.3±20.8                                   16--78
  Wang et al 2013[68](#jah33353-bib-0068){ref-type="ref"}                                                 8                                            2                                                                                              20                           2                                                        100                                                        0     0     1                                          50    1                                           50    n/a                                         n/a
  Ware et al 2014[69](#jah33353-bib-0069){ref-type="ref"}                                                 7                                            2                                                                                              20                           2                                                        100                                                        0     0     0                                          0     2                                           100   17                                          ···
  Warnes et al 1985[70](#jah33353-bib-0070){ref-type="ref"}                                               2                                            2                                                                                              33                           2                                                        100                                                        0     0     0                                          0     2                                           100   35.0±18.4                                   22--48
  Weigang et al 2007[71](#jah33353-bib-0071){ref-type="ref"}                                              23                                           9                                                                                              35                           5                                                        56                                                         0     0     3                                          33    6                                           67    32[c](#jah33353-note-0013){ref-type="fn"}   18--47
  Yoo et al 2010[72](#jah33353-bib-0072){ref-type="ref"}                                                  6                                            5                                                                                              25                           1                                                        20                                                         0     0     0                                          0     5                                           100   32.5±12.9                                   20--46
  Zhu et al 2006[73](#jah33353-bib-0073){ref-type="ref"}                                                  49                                           8                                                                                              16                           7                                                        88                                                         n/a   ···   5                                          63    3                                           38    n/a                                         n/a
  Ziganshin et al 2015[74](#jah33353-bib-0074){ref-type="ref"}, [f](#jah33353-note-0016){ref-type="fn"}   15                                           4                                                                                              15                           2                                                        50                                                         n/a   ···   1                                          25    3                                           75    n/a                                         n/a
  Ziganshin et al 2015[74](#jah33353-bib-0074){ref-type="ref"}, [f](#jah33353-note-0016){ref-type="fn"}   15                                           7                                                                                              41                           4                                                        57                                                         n/a   ···   4                                          57    3                                           43    n/a                                         n/a

n/a indicates not available.

Percentage calculated in the family pedigree (as per protocol).

Median available only.

Data available from 4 families only (TAA288, TAA062, TAA549, TAA395).

Mean available only.

Comprehensive of patients affected by bicuspid aortic valve.

Data of 2 different screened families obtained from the same study.

![Relatives screened in the studies included in the systematic review. Details for newly affected and not screened individuals are provided for first‐, second‐, and third‐degree relatives (FDRs, SDRs, and TDRs, respectively).](JAH3-7-e009302-g001){#jah33353-fig-0001}

A total of 893 FDRs, 695 SDRs, and 670 TDRs were identified in the family pedigrees of the included studies (Table [S5](#jah33353-sup-0001){ref-type="supplementary-material"}). Of these, a total of 910 newly affected relatives were detected, with an average among studies of 22 newly diagnosed individuals. The percentage of newly diagnosed relatives was 23% (study range: 6--56%). Newly diagnosed individuals were male in 67% of the cases (study range: 20--100%). Sudden unexplained deaths were reported in 2% of the cases (study range: 0--9%). Detailed data about rates of newly affected and screened FDRs, SDRs, and TDRs are depicted in Figure [1](#jah33353-fig-0001){ref-type="fig"}.

The type of aortic diseases (aneurysm and dissection rates), male preponderance rate, and age at dissection are summarized in Table [2](#jah33353-tbl-0002){ref-type="table"} and Table [S4](#jah33353-sup-0001){ref-type="supplementary-material"}. Only 1 study screened the relatives of 53 probands identified as affected by a sporadic NS‐TAD form, identifying 83 of 321 newly affected relatives.[59](#jah33353-bib-0059){ref-type="ref"}

Results of Genetic Tests {#jah33353-sec-0021}
------------------------

The techniques used in the genetic screening, the identified genes, and genetic mutations are listed in Table [S8](#jah33353-sup-0001){ref-type="supplementary-material"}. Genetic screening was employed as the sole screening modality in 26 (49%) studies and in combination with imaging modalities in 21 (40%). A total of 14 known genes were identified as a causative mutation for NS‐TADs, while 3 mapped loci without an identified gene were also found (Table [3](#jah33353-tbl-0003){ref-type="table"} and Table [S11](#jah33353-sup-0001){ref-type="supplementary-material"}). Single‐gene testing was used in 24 (45%) studies, comprehensive genomic sequencing in 14 (26%), and a combination of the 2 approaches in 7 (13%), respectively (Figure [2](#jah33353-fig-0002){ref-type="fig"}, Tables [S8](#jah33353-sup-0001){ref-type="supplementary-material"} and [S10](#jah33353-sup-0001){ref-type="supplementary-material"}).

###### 

Genetic Mutations and Correlations With Age and Size at Dissection[a](#jah33353-note-0018){ref-type="fn"}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study (Author/Y)                                                   Patients Affected (Aneurysm+Dissection)   Aortic Dissection                                                                                                                                                            
  ------------------------------------------------------------------ ----------------------------------------- ------------------- ----- ----- ----- ----- ---------------------------------------------------------- -------- -------------------------------------------------- --------- -----
  ACTA 2                                                                                                                                                                                                                                                                                    

  Chamney et al 2015[24](#jah33353-bib-0024){ref-type="ref"}         6                                         43                  3     50    3     100   49±10.4[e](#jah33353-note-0022){ref-type="fn"}             37--55   n/a                                                ···       ···

  Disabella et al 2011[25](#jah33353-bib-0025){ref-type="ref"}       15                                        41                  9     60    5     56    49.3±16.3[e](#jah33353-note-0022){ref-type="fn"}           29--73   59.1±22.3[e](#jah33353-note-0022){ref-type="fn"}   41--95    7

  Guo et al 2007[32](#jah33353-bib-0032){ref-type="ref"}             53                                        25                  45    85    23    51    37.3±13.9[e](#jah33353-note-0022){ref-type="fn"}           13--67   61.1±15.0[e](#jah33353-note-0022){ref-type="fn"}   45--100   12

  Morisaki et al 2009[52](#jah33353-bib-0052){ref-type="ref"}        14                                        30                  11    79    9     82    36.8±10.1[e](#jah33353-note-0022){ref-type="fn"}           25--52   n/a                                                ···       ···

  Renard et al 2013[58](#jah33353-bib-0058){ref-type="ref"}          26                                        32                  13    79    7     54    40.7±15.4[e](#jah33353-note-0022){ref-type="fn"}           27--70   n/a                                                ···       ···

  Ware et al 2014[69](#jah33353-bib-0069){ref-type="ref"}            2                                         20                  2     100   2     100   17                                                         ···      53±7.1[e](#jah33353-note-0022){ref-type="fn"}      48--58    2

  Yoo et al 2010[72](#jah33353-bib-0072){ref-type="ref"}             5                                         25                  5     100   1     20    32.5±12.9[e](#jah33353-note-0022){ref-type="fn"}           20--46   35                                                 ···       1

  FBN1                                                                                                                                                                                                                                                                                      

  Francke et al 1995[28](#jah33353-bib-0028){ref-type="ref"}         10                                        38                  3     30    2     67    55±14.1[e](#jah33353-note-0022){ref-type="fn"}             45--65   n/a                                                ···       ···

  Regalado et al 2016[37](#jah33353-bib-0037){ref-type="ref"}        15                                        52                  8     53    4     50    32.3±9.9[e](#jah33353-note-0022){ref-type="fn"}            18--50   44                                                 ···       1

  FOXE3                                                                                                                                                                                                                                                                                     

  Kuang et al 2016[47](#jah33353-bib-0047){ref-type="ref"}           11                                        28                  11    100   11    100   44.3±22.6[e](#jah33353-note-0022){ref-type="fn"}           9--88    n/a                                                ···       ···

  LOX                                                                                                                                                                                                                                                                                       

  Guo et al 2016[37](#jah33353-bib-0037){ref-type="ref"}             21                                        32                  4     19    4     100   44.8±15.1[e](#jah33353-note-0022){ref-type="fn"}           25--60   n/a                                                ···       ···

  MYH11                                                                                                                                                                                                                                                                                     

  Harakalova et al 2013[40](#jah33353-bib-0040){ref-type="ref"}      15                                        20                  10    67    7     70    46.6±19.5[e](#jah33353-note-0022){ref-type="fn"}           18--70   58.5±17.3[e](#jah33353-note-0022){ref-type="fn"}   44--65    4

  Khau Van Kien et al 2005[46](#jah33353-bib-0046){ref-type="ref"}   8                                         9                   4     50    3     75    n/a                                                        ···      n/a                                                ···       ···

  Pannu et al 2008[56](#jah33353-bib-0056){ref-type="ref"}           6                                         22                  5     83    4     80    45±8.8[e](#jah33353-note-0022){ref-type="fn"}              37--56   44                                                 ···       1

  Renard et al 2013[58](#jah33353-bib-0058){ref-type="ref"}          3                                         20                  2     83    1     50    48.0±21.2[e](#jah33353-note-0022){ref-type="fn"}           33--63   n/a                                                ···       ···

  Takeda et al 2015[61](#jah33353-bib-0061){ref-type="ref"}          5                                         29                  4     80    4     100   47.8±16.6[e](#jah33353-note-0022){ref-type="fn"}           32--70   n/a                                                ···       ···

  Zhu et al 2006[73](#jah33353-bib-0073){ref-type="ref"}             8                                         16                  3     38    2     67    n/a                                                        ···      37.3±7.8[b](#jah33353-note-0019){ref-type="fn"}    n/a       2

  MYLK                                                                                                                                                                                                                                                                                      

  Hannuksela et al 2016[39](#jah33353-bib-0039){ref-type="ref"}      6                                         13                  6     100   5     83    53.2±21.1[e](#jah33353-note-0022){ref-type="fn"}           23--75   47.5±0.7[e](#jah33353-note-0022){ref-type="fn"}    47--48    2

  Wang et al 2010[66](#jah33353-bib-0066){ref-type="ref"}            10                                        21                  10    100   5     50    54.3±20.8[e](#jah33353-note-0022){ref-type="fn"}           16--78   40                                                 ···       1

  Ziganshin et al 2015[74](#jah33353-bib-0074){ref-type="ref"}       4                                         15                  3     75    1     33    n/a                                                        ···      n/a                                                ···       ···

  PRKG1                                                                                                                                                                                                                                                                                     

  Gago‐Diaz et al 2016[30](#jah33353-bib-0030){ref-type="ref"}       11                                        37                  6     55    3     50    34.2±12.9[e](#jah33353-note-0022){ref-type="fn"}           15--48   43±1.4[e](#jah33353-note-0022){ref-type="fn"}      42--44    2

  Guo et al 2013[35](#jah33353-bib-0035){ref-type="ref"}             37                                        42                  22    59    10    45    31.1±10.3[e](#jah33353-note-0022){ref-type="fn"}           17--51   47±14.1[e](#jah33353-note-0022){ref-type="fn"}     37--57    2

  SMAD3                                                                                                                                                                                                                                                                                     

  Regalado et al 2011[56](#jah33353-bib-0056){ref-type="ref"}        23                                        22                  14    61    n/a   n/a   42[c](#jah33353-note-0020){ref-type="fn"}                  25--54   50                                                 50        1

  TGFB2                                                                                                                                                                                                                                                                                     

  Gago‐Diaz et al 2014[29](#jah33353-bib-0029){ref-type="ref"}       6                                         19                  2     33    2     100   37.5±4.9[e](#jah33353-note-0022){ref-type="fn"}            34--41   n/a                                                ···       ···

  TGFBR1                                                                                                                                                                                                                                                                                    

  Dong et al 2014[27](#jah33353-bib-0027){ref-type="ref"}            9                                         14                  3     33    3     100   39±6.9[e](#jah33353-note-0022){ref-type="fn"}              35--47   51.3±17.9[e](#jah33353-note-0022){ref-type="fn"}   40--72    3

  Tran‐Fadulo et al 2009[64](#jah33353-bib-0064){ref-type="ref"}     29                                        37                  14    48    10    71    25.6±14.3 (male)[d](#jah33353-note-0021){ref-type="fn"}\   14--62   90.6±42.7[e](#jah33353-note-0022){ref-type="fn"}   65--140   2
                                                                                                                                                           38.6±9.7 (female)                                                                                                                

  Ziganshin et al 2015[74](#jah33353-bib-0074){ref-type="ref"}       7                                         41                  3     43    2     67    n/a                                                        ···      n/a                                                ···       ···

  TGFBR2                                                                                                                                                                                                                                                                                    

  Hasham et al 2003[41](#jah33353-bib-0041){ref-type="ref"}          17                                        25                  8     47    6     75    45.4±21.5[e](#jah33353-note-0022){ref-type="fn"}           14--72   n/a                                                ···       ···

  Pannu et al 2005[53](#jah33353-bib-0053){ref-type="ref"}           59                                        25                  32    54    22    69    46.1±16.3[e](#jah33353-note-0022){ref-type="fn"}           14--73   n/a                                                ···       ···

  Tran‐Fadulo et al 2009[65](#jah33353-bib-0065){ref-type="ref"}     n/a                                       ···                 n/a   ···   n/a   ···   42.6±17.8 (male)[d](#jah33353-note-0021){ref-type="fn"}\   n/a      44±2.8[e](#jah33353-note-0022){ref-type="fn"}      42--46    2
                                                                                                                                                           51.3±17.1 (female)                                                                                                               
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

n/a indicates not available.

No data available for patients affected by aortic dissection regarding the genes NOTCH1 (reference [22](#jah33353-bib-0022){ref-type="ref"}) and MFAP5 (reference [1](#jah33353-bib-0001){ref-type="ref"}), and patients with MAT2A mutation did not experience aortic dissections (reference 15).

Data available for dissection of the descending thoracic aorta only.

Average age onset of dissection as presented by the authors.

Derived from the entire cohort of patients with TGFBR1 and TGFBR2 mutations.

Expressed as mean±SD.

![Schematic representation of genetic mutations with age and ascending aorta diameter at dissection. The widening of the circles/lines represents SD in terms of age and diameters. Data are obtained from studies included in the systematic review. No numerical data were available for patients affected by aortic dissection regarding the genes NOTCH1 and MFAP5, and patients with MAT2A mutation did not experience aortic dissections.[1](#jah33353-bib-0001){ref-type="ref"}, [36](#jah33353-bib-0036){ref-type="ref"}, [43](#jah33353-bib-0043){ref-type="ref"}](JAH3-7-e009302-g002){#jah33353-fig-0002}

The inheritance mode was essentially autosomal dominant (Table [1](#jah33353-tbl-0001){ref-type="table"}). Forty‐one (79%) studies reported on the penetrance of the NS‐TAD. Penetrance varied in relationship to the NS‐TAD form, with an average of 67% (study range: 20--100%) and was lower in females (Table [2](#jah33353-tbl-0002){ref-type="table"}). The age at dissection varied according to the underlying NS‐TAD form, with a mean age of presentation of 32 years for the familial thoracic aortic aneurysm and dissection forms associated with the mutations of the PRKG1 gene and of 54 years for those associated with the mutation of the MYLK gene (Figure [2](#jah33353-fig-0002){ref-type="fig"} and Table [3](#jah33353-tbl-0003){ref-type="table"}). Ascending aortic diameters at the time of acute dissection were not reported for most of the individuals. Where this was reported, individuals affected by NS‐TADs showed stratification of the diameter of the thoracic aorta (aortic root, mid ascending, or descending aorta) at dissection and in the risk of progression to dissection by genetic mutation: from \<4.5 cm for FBN1, FOXE2, MILK, PRKG1, SMAD3, TGFB2, TGFBR1, and TGFBR2, to \>5.5 cm for ACTA2, LOX, and MYH11, respectively (Figure [2](#jah33353-fig-0002){ref-type="fig"}, Table [S10](#jah33353-sup-0001){ref-type="supplementary-material"}). The identified NS‐TAD forms presented specific characteristics based on the causative genetic mutation (Tables [1](#jah33353-tbl-0001){ref-type="table"} and [3](#jah33353-tbl-0003){ref-type="table"}, Table [S10](#jah33353-sup-0001){ref-type="supplementary-material"}, and Figure [S2](#jah33353-sup-0001){ref-type="supplementary-material"}).

Extra‐Aortic Manifestations of NS‐TAD {#jah33353-sec-0022}
-------------------------------------

Concomitant cardiovascular diseases were diagnosed in 11% of the relatives undergoing screening, while concomitant physical abnormalities were observed in 18% of the cases. Full details of all described external physical features and abnormalities of other organ systems are reported in Table [S6](#jah33353-sup-0001){ref-type="supplementary-material"}.

Resource Use and Cost‐Effectiveness {#jah33353-sec-0023}
-----------------------------------

No information about resource use and the cost‐effectiveness of screening program in relatives of patients with NS‐TAD was reported in any of the identified studies. No studies address the psychological effect of screening in patients and their relative or its impact on quality of life of these families.

Discussion {#jah33353-sec-0024}
==========

Main Findings {#jah33353-sec-0025}
-------------

The present study has identified an area of unmet clinical need with respect to screening of relatives of patients with NS‐TAD: familial NS‐TADs occur more frequently than previously recognized, affecting ≈30% of relatives with a male predominance (3:1). These are primarily inherited as single gene mutations, expressed in an autosomal dominant pattern with incomplete penetrance, which demonstrate variable expression with respect to age of presentation, sex, aneurysmal location, and aortic diameter before dissection. The risk of acute aortic syndrome is determined by the underlying genetic mutation and this risk extends not only to FDRs but also to SDRs and TDRs of patients affected by NS‐TADs. There is an overlap between nonsyndromic and syndromic TADs for some genetic mutations, as well as concomitant cardiovascular pathology in over 10% of screened patients. The review also identified knowledge gaps with respect to the predictive accuracy of commonly used screening tests across NS‐TAD populations, the optimal structure and extent of a screening program across families, and the effectiveness of a screening program with respect to clinical outcomes or cost.

Clinical Implications {#jah33353-sec-0026}
---------------------

Nonsyndromic aortopathies have poor prognosis if untreated and the lack of relevant physical features precludes identification based on a clinical characteristics alone.[7](#jah33353-bib-0007){ref-type="ref"}, [75](#jah33353-bib-0075){ref-type="ref"} As a consequence, NS‐TADs are asymptomatic, alerting clinicians to the underlining aortopathy only when sudden death or an acute aortic dissection occurs.[7](#jah33353-bib-0007){ref-type="ref"}, [19](#jah33353-bib-0019){ref-type="ref"}, [72](#jah33353-bib-0072){ref-type="ref"}, [75](#jah33353-bib-0075){ref-type="ref"} This review indicates that routine screening and surveillance programs in relatives of patients affected by NS‐TADs, similar to those of syndromic TAD, are likely to identify significant numbers of patients with asymptomatic NS‐TAD.[4](#jah33353-bib-0004){ref-type="ref"}, [5](#jah33353-bib-0005){ref-type="ref"}, [76](#jah33353-bib-0076){ref-type="ref"}, [77](#jah33353-bib-0077){ref-type="ref"} The overlap in genetic mutations between NS‐TAD and syndromic TAD identified in the review further support this assertion. It follows that diagnosis, surveillance, and treatment of NS‐TADs before clinical presentation, as is the standard of care for syndromic TAD, is likely to reduce premature deaths. The findings of this article also indicate that current guidelines which recommend treatment based predominantly on the aortic diameter are likely to result in the undertreatment of NS‐TADs.[4](#jah33353-bib-0004){ref-type="ref"}, [5](#jah33353-bib-0005){ref-type="ref"} Specifically, subtypes of NS‐TADs attributed to specific genetic mutations may progress to aortic dissection without aneurysm formation.[78](#jah33353-bib-0078){ref-type="ref"} Here, the treatment of affected relatives stratified by NS‐TAD subtype and genetic abnormality are likely to result in further clinical benefits (Figure [2](#jah33353-fig-0002){ref-type="fig"}).

In addition to defining an area of unmet need, the review has identified important knowledge gaps with respect to screening. Specifically, the diagnostic accuracy of existing screening tests, the optimal screening program, and the clinical, societal, or economic benefits of such a screening program in the relatives of patients with sporadic or familial NS‐TAD are unclear. Current guidelines for the diagnosis and treatment of aortic diseases do not specify the details of what screening tests should be used (Table [S11](#jah33353-sup-0001){ref-type="supplementary-material"}).[4](#jah33353-bib-0004){ref-type="ref"}, [5](#jah33353-bib-0005){ref-type="ref"}, [77](#jah33353-bib-0077){ref-type="ref"} The 2014 European Society of Cardiology guidelines recommend investigating FDRs by genetic counseling for family investigation and molecular testing, with a 5‐year interval screening until diagnosis (clinical or molecular) is established or ruled out (class I, level of evidence C).[5](#jah33353-bib-0005){ref-type="ref"} The corresponding 2010 American guidelines suggest aortic imaging screening for FDRs along with counseling and testing whether a specific mutant gene (FBN1, TGFBR1, TGFBR2, COL3A1, ACTA2, MYH11) is identified in the affected probands (class I, level of evidence C).[4](#jah33353-bib-0004){ref-type="ref"} These recommendations are based on opinion of the experts and small group studies only.[4](#jah33353-bib-0004){ref-type="ref"}, [5](#jah33353-bib-0005){ref-type="ref"} Importantly, specific testing schedules, the requirement for screening of SDRs and TDRs, the need for sequencing of other less‐common mutant genes, the optimal screening interval and modality, or the need to investigate the entire arterial tree other than the thoracic aorta are not specified.[4](#jah33353-bib-0004){ref-type="ref"}, [5](#jah33353-bib-0005){ref-type="ref"} The results of the current study suggest that FDRs, SDRs, and possibly TDRs should be offered screening for TAD. Clarification of the family history regarding the location of the aortic disease, the specific nature of "sudden deaths," or the presence of other concomitant cardiovascular disorders during clinical examination should represent the initial step of screening.[75](#jah33353-bib-0075){ref-type="ref"} Our results also suggest that genetic testing and cardiac imaging with at least TTE should be offered to all FDRs and SDRs of patients with suspected NS‐TADs. Mutation carriers should undergo further imaging (MRI or CT scan), focusing on thoracic aorta and/or other arterial trees based on the causative gene mutation.[22](#jah33353-bib-0022){ref-type="ref"}, [23](#jah33353-bib-0023){ref-type="ref"}, [24](#jah33353-bib-0024){ref-type="ref"}, [25](#jah33353-bib-0025){ref-type="ref"}, [26](#jah33353-bib-0026){ref-type="ref"}, [27](#jah33353-bib-0027){ref-type="ref"}, [28](#jah33353-bib-0028){ref-type="ref"}, [29](#jah33353-bib-0029){ref-type="ref"}, [30](#jah33353-bib-0030){ref-type="ref"}, [31](#jah33353-bib-0031){ref-type="ref"}, [32](#jah33353-bib-0032){ref-type="ref"}, [33](#jah33353-bib-0033){ref-type="ref"}, [34](#jah33353-bib-0034){ref-type="ref"}, [35](#jah33353-bib-0035){ref-type="ref"}, [36](#jah33353-bib-0036){ref-type="ref"}, [37](#jah33353-bib-0037){ref-type="ref"}, [38](#jah33353-bib-0038){ref-type="ref"}, [39](#jah33353-bib-0039){ref-type="ref"}, [40](#jah33353-bib-0040){ref-type="ref"}, [41](#jah33353-bib-0041){ref-type="ref"}, [42](#jah33353-bib-0042){ref-type="ref"}, [43](#jah33353-bib-0043){ref-type="ref"}, [44](#jah33353-bib-0044){ref-type="ref"}, [45](#jah33353-bib-0045){ref-type="ref"}, [46](#jah33353-bib-0046){ref-type="ref"}, [47](#jah33353-bib-0047){ref-type="ref"}, [48](#jah33353-bib-0048){ref-type="ref"}, [49](#jah33353-bib-0049){ref-type="ref"}, [50](#jah33353-bib-0050){ref-type="ref"}, [51](#jah33353-bib-0051){ref-type="ref"}, [52](#jah33353-bib-0052){ref-type="ref"}, [53](#jah33353-bib-0053){ref-type="ref"}, [54](#jah33353-bib-0054){ref-type="ref"}, [55](#jah33353-bib-0055){ref-type="ref"}, [56](#jah33353-bib-0056){ref-type="ref"}, [57](#jah33353-bib-0057){ref-type="ref"}, [58](#jah33353-bib-0058){ref-type="ref"}, [59](#jah33353-bib-0059){ref-type="ref"}, [60](#jah33353-bib-0060){ref-type="ref"}, [61](#jah33353-bib-0061){ref-type="ref"}, [62](#jah33353-bib-0062){ref-type="ref"}, [63](#jah33353-bib-0063){ref-type="ref"}, [64](#jah33353-bib-0064){ref-type="ref"}, [65](#jah33353-bib-0065){ref-type="ref"}, [66](#jah33353-bib-0066){ref-type="ref"}, [67](#jah33353-bib-0067){ref-type="ref"}, [68](#jah33353-bib-0068){ref-type="ref"}, [69](#jah33353-bib-0069){ref-type="ref"}, [70](#jah33353-bib-0070){ref-type="ref"}, [71](#jah33353-bib-0071){ref-type="ref"}, [72](#jah33353-bib-0072){ref-type="ref"}, [73](#jah33353-bib-0073){ref-type="ref"}, [74](#jah33353-bib-0074){ref-type="ref"} For example, ACTA2‐mutation carriers should be monitored for coronary artery disease and occlusive cerebrovascular disease, in addition to the currently recommended routine imaging tests.[32](#jah33353-bib-0032){ref-type="ref"} We suggest that complete aortic imaging at initial diagnosis and at 6 months for patients with a confirmed genetic aortopathy (eg, FBN1, FOXE3, MFAP5, MYLK, PRKG1, SMAD3, TGFB2, TGFBR1, and TGFBR2) should be obtained to establish whether aortic enlargement is occurring.[4](#jah33353-bib-0004){ref-type="ref"}, [74](#jah33353-bib-0074){ref-type="ref"} The final clinical management of patients with a specific gene mutation could be modified on the basis of these data, enabling personalized treatment that is independent of the native aortic diameters.[4](#jah33353-bib-0004){ref-type="ref"}, [5](#jah33353-bib-0005){ref-type="ref"}, [41](#jah33353-bib-0041){ref-type="ref"}, [50](#jah33353-bib-0050){ref-type="ref"} Only relatives in whom a causal mutation is excluded and the aortic size is within recommended diameters should reasonably undergo clinical and/or imaging screening every 2 to 5 years, until diagnosis is confirmed or ruled out.[5](#jah33353-bib-0005){ref-type="ref"}, [76](#jah33353-bib-0076){ref-type="ref"} The appropriate temporal interval for follow‐up imaging, as well as the starting age for aortic surveillance, are also poorly defined. Generally, patients with NS‐TAD are diagnosed on average 10 years older than patients affected by syndromic aortopathies, being also characterized by a lower annual aortic dilatation progression (0.5--0.7 mm/y).[59](#jah33353-bib-0059){ref-type="ref"}, [60](#jah33353-bib-0060){ref-type="ref"} It therefore seems reasonable to initiate the screening 15 to 10 years earlier than first aneurysm or when dissection or sudden death is recorded within the family.[60](#jah33353-bib-0060){ref-type="ref"}, [79](#jah33353-bib-0079){ref-type="ref"} A screening pathway based on these observations is proposed in Figure [3](#jah33353-fig-0003){ref-type="fig"}.

![Proposed flow chart for a dedicated screening program for relatives of patients affected by nonsyndromic diseases of the thoracic aorta based on the authors' extensive literature review. The figure represents the best judgement of the authors. BAV indicates bicuspid aortic valve; CT, computed tomography; FDRs, first‐degree relatives; MRI, magnetic resonance imaging; NS‐TAD, nonsyndromic thoracic aortic disease; SDRs, second‐degree relatives; TTE, transthoracic echocardiogram.](JAH3-7-e009302-g003){#jah33353-fig-0003}

There are several additional factors that may influence our proposed screening algorithm. First, variable penetrance, which often characterizes NS‐TAD forms, is a potential confounder. This results in intrafamilial variability, which is evident not only with reference to the aortopathy itself (severity, age of onset), but also with regard to other phenotypic manifestations.[65](#jah33353-bib-0065){ref-type="ref"}, [66](#jah33353-bib-0066){ref-type="ref"}, [67](#jah33353-bib-0067){ref-type="ref"}, [68](#jah33353-bib-0068){ref-type="ref"}, [69](#jah33353-bib-0069){ref-type="ref"}, [70](#jah33353-bib-0070){ref-type="ref"}, [71](#jah33353-bib-0071){ref-type="ref"}, [72](#jah33353-bib-0072){ref-type="ref"}, [73](#jah33353-bib-0073){ref-type="ref"}, [74](#jah33353-bib-0074){ref-type="ref"}, [75](#jah33353-bib-0075){ref-type="ref"}, [76](#jah33353-bib-0076){ref-type="ref"}, [77](#jah33353-bib-0077){ref-type="ref"}, [78](#jah33353-bib-0078){ref-type="ref"}, [79](#jah33353-bib-0079){ref-type="ref"}, [80](#jah33353-bib-0080){ref-type="ref"}, [81](#jah33353-bib-0081){ref-type="ref"} The presence of associated features is certainly suggestive of having inherited the aortic condition along with the predisposition to the aortopathy, but the absence of these associated features does not eliminate the risk of having an underlying aortopathy. Second, women often demonstrate a lower lifetime risk of aortopathy, developing the condition at a later age than men.[81](#jah33353-bib-0081){ref-type="ref"} This phenomenon, known as sexual dimorphism, explains the apparent paradox of an affected teenager with an affected maternal grandfather but an unaffected mother with normal echocardiographic features. Third, the age at onset of the aortopathy may be important in the natural history of the disease. Ma et al[82](#jah33353-bib-0082){ref-type="ref"} recently demonstrated that age at onset of aortic dissection is lower in families with a positive history for aortic dissection, therefore suggesting a prompt and more aggressive screening pathway in these families. A positive family history with an aortopathy occurring at younger ages confers a significantly increased risk of developing a new dissection in apparently unaffected family members.[81](#jah33353-bib-0081){ref-type="ref"} The above findings are all important in guiding the proper screening and surveillance strategies.

Study Limitations {#jah33353-sec-0027}
-----------------

The most important limitation of the review is the uncertainty regarding the likely yield of new cases if a screening program were to be implemented. The studies identified in our searches were predominantly studies of familial aortopathy, and the prevalence of TAD in these populations will not reflect that for NS‐TAD overall. Conversely, sporadic NS‐TAD, which constitutes the majority (80%) of all cases also has a genetic component.[7](#jah33353-bib-0007){ref-type="ref"} Roberston et al[59](#jah33353-bib-0059){ref-type="ref"} investigating 321 NS‐TAD probands who had no family history of TAD identified 27% of newly affected relatives. It is likely that these patients are carriers of a de novo mutation, making these "sporadic" patients founders of a new nonsyndromic aortopathy. For example, recent studies have identified gene deletions and uniparental disomy, and genetic variations in LRP1 and ULK4 in sporadic NS‐TAD.[83](#jah33353-bib-0083){ref-type="ref"} This suggests that the relatives of patients affected by both familial and sporadic NS‐TADs may benefit from screening. It also argues for use of nontargeted genetic screening tests such as exome or whole genome sequencing that will detect de novo or as‐yet unrecognized common mutations. A second limitation is that there is currently no evidence to inform secondary prevention or intervention strategies in newly diagnosed NS‐TAD, particularly where the aorta is phenotypically normal. Although the evidence presented supports the routine implementation of combined imaging and genetic testing in relatives of patients with NS‐TAD, no study has proven that stratified treatment, independent of the native aortic diameter, will save lives. However, the stratified treatment of syndromic TAD is common practice, as this is known to prevent deaths from aortic disease. We suggest that the results of this review support the extension of similar programs to all patients with TAD. To address these limitations, we propose that further research should first establish the true prevalence of genetic abnormalities and phenotypic disease diagnosed by screening (genetic testing and imaging) all FDRs and SDRs of patients with both familial and sporadic NS‐TAD. Further studies will be required to address uncertainty with respect to effectiveness, psychological impact, and the costs of lifelong screening in these groups. Finally, the heterogeneity of the included studies, the large period of publication across 3 decades, and the familial‐based approach have limited our ability to analyze the impact of region or ethnicity in the risk of aortopathies and the related screening strategy.

Conclusions {#jah33353-sec-0028}
===========

The findings of this review support routine imaging and genetic testing of relatives of patients with nonsyndromic aortopathies. The evidence suggests that screening of FDRs and SDRs of patients affected by familial NS‐TAD and FDRs of those affected by sporadic NS‐TADs will result in significant numbers of patients with otherwise undiagnosed disease. Personalized screening programs determined by the subtype of NS‐TAD and its related genetic mutation have the potential to benefit these patients. However, the diagnostic yield of available screening tests is unclear, as are the details of a screening program, and there is no existing evidence that routine screening and stratified treatment will have clinical or economic benefits. Further studies are required to address these knowledge gaps.
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